Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study. Issue 1 (6th August 2021)

• Record Type: Journal Article
• Authors: Kong, Xiufang; Sun, Ying; Dai, Xiaojuan; Wang, Li; Ji, Zongfei; Chen, Huiyong; Jin, Xuejuan; Ma, Lili; Jiang, Lindi
• Is Part Of: Annals of the rheumatic diseases. Volume 81:Issue 1(2022)
• Page Start: 117
• Page End: 123
• Publication Date: 2021-08-06
• Subjects: autoimmune diseases -- outcome assessment -- health care -- therapeutics; Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2021-220832
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Objective: To compare the treatment efficacy and safety of tofacitinib (TOF) versus methotrexate (MTX) in Takayasu arteritis (TAK). Methods: Fifty-three patients with active disease from an ongoing prospective TAK cohort in China were included in this study. Twenty-seven patients were treated with glucocorticoids (GCs) and TOF, and 26 patients were treated with GCs with MTX. The observation period was 12 months. Complete remission (CR), inflammatory parameter changes, GCs tapering and safety were assessed at the 6th, 9th and 12th month. Vascular lesions were evaluated at the 6th and 12th month, and relapse was analysed during 12 months. Results: The CR rate was higher in the TOF group than in the MTX group (6 months: 85.19% vs 61.54%, p=0.07; 12 months: 88.46% vs 56.52%, p=0.02). During 12 months' treatment, patients in the TOF group achieved a relatively lower relapse rate (11.54% vs 34.78%, p=0.052) and a longer median relapse-free duration (11.65±0.98 vs 10.48±2.31 months, p=0.03). Average GCs dose at the 3rd, 6th and 12th month was lower in the TOF group than that in the MTX group (p<0.05). A difference was not observed in disease improvement or disease progression on imaging between the two groups (p>0.05). Prevalence of side effects was low in both groups (3.70% vs 15.38%, p=0.19). Conclusion: TOF was superior to MTX for CR induction, a tendency to prevent relapse and tapering of the GCs dose in TAK treatment. A good safety profile for TOF was also documented in patients with TAK.